



**RCOphth Annual Congress 2018**

## **Managing retinal dystrophies**

**Tuesday 22 May 2018 11.00 – 13.00**

**Chaired by Mr Andrew Webster, Professor of Molecular Ophthalmology, UCL & Consultant Ophthalmologist, Moorfields Eye Hospital & Mr Omar Mahroo, St Thomas' Hospital and King's College London**

Retinal dystrophies, although individually rare, cumulatively remain a significant cause of untreatable blindness in working-age adults in the UK. In this session, experts in the field discuss how recent advances in genomic medicine, clinical investigation and assistive technology are allowing ophthalmologists to improve the management of patients and families. We emphasise the practical aspects of management possible at the present time. Also, with a recent clinical endorsement of a gene-therapy for one rare type of dystrophy, there is more optimism than ever that preventative treatments will impact management in the future and we will discuss the current trials in this area.

- |                      |  |
|----------------------|--|
| <b>11.00 – 11.20</b> | <b>Gene therapy for inherited retinal disease – RPE65 a paradigm?</b><br>Dr Stephen Russell, University of Iowa USA                                  |
| <b>11.20 – 11.40</b> | <b>Managing Inherited retinal disease in children</b><br>Professor Michel Michaelides , University College London and Moorfields Eye Hospital        |
| <b>11.40 – 12.00</b> | <b>Genetic testing for inherited retinal disease</b><br>Mr Andrew Webster  |
| <b>12.00 – 12.20</b> | <b>Counselling patients and families</b><br>Miss Georgina Hall, Central Manchester NHS Foundation Trust  |
| <b>12.20 – 12.40</b> | <b>Electrophysiology – when to request and what it means.</b><br>Mr Omar Mahroo, King's College and St Thomas's Hospital                             |
| <b>12.40 – 13.00</b> | <b>How assistive technology is transforming low vision management</b><br>Dr Michael Crossland, University College London and Moorfields Eye Hospital |